Biodexa Pharmaceuticals Initiates Phase 2 Study for Type 1 Diabetes Treatment

Biodexa Pharmaceuticals ( (BDRX) ) just unveiled an announcement.

On June 4, 2025, Biodexa Pharmaceuticals announced the recruitment of the first patient in a Phase 2 study of tolimidone for Type 1 Diabetes. This study, conducted by the University of Alberta Diabetes Institute, aims to evaluate the efficacy of tolimidone by measuring C-peptide levels and HbA1c over three months. The study’s initiation marks a significant step in Biodexa’s efforts to address unmet medical needs in diabetes treatment, potentially enhancing its position in the biopharmaceutical industry.

The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.

Spark’s Take on BDRX Stock

According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.

Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.

To see Spark’s full report on BDRX stock, click here.

More about Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs. The company is working on several lead development programs including eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer indications. Biodexa is headquartered in Cardiff, UK.

Average Trading Volume: 2,615,130

Technical Sentiment Signal: Sell

Current Market Cap: $768.9K

Find detailed analytics on BDRX stock on TipRanks’ Stock Analysis page.